A Novel Intra-oral Mucosal Tissue Delivery Platform for Oral and Systemic Health Applications

Abstract Description:
The development of optimal and safe intra-oral tissue delivery of exogenous materials remains a major
challenge despite the well-known inherent advantages (great blood supply) and great potential of this
delivery route as it avoids pre-systemic elimination in the gastrointestinal tract and bypasses the first
hepatic metabolism. Periodontitis and peri-implantitis are chronic inflammatory diseases with micro
biological and immunological pathways to systemic chronic inflammatory diseases. Specific “Gateway”
oral pathogens create a systemic dysbiotic chronic disease state that is difficult to reverse. The immune
system is alerted, recruited and subverted, creating chronic oral inflammatory reactions where these
circulating pathogens and associated inflammatory factors such as lipopolysaccharides (LPS) and
gingipains penetrate through the junctional epithelium and are carried throughout the body. These affect
the endothelial cells of arteries and infect the arterial walls and neural tissues, creating a systemic
inflammatory reaction, compromising the blood brain barrier and CNS, as well as the cardiac, respiratory,
renal tissues, and the gastrointestinal tract. A review of the immunological cellular processes,
treatment challenges and a novel proprietary improved oral mucosal tissue delivery platform for more
effectively treating these conditions will be discussed.

Author’s Biography:
A graduate of the Columbia University College of Dental Medicine, Dr. Sanders, who has advanced
training in dental trauma and surgery, maintained a high-end private dental practice in Mid-Manhattan.
He has done extensive research and testing for CR (Clinicians Report) a premier independent research
institute in the USA for testing new dental products and materials.

Dr. Sanders is an innovator and visionary in the dental field, with over 50 international utility patents
granted on numerous dental/oral devices/systems including the TheraSmile® automated delivery system
and the disposable elastomeric oral tissue mavguards®.

Dr. Sanders is Founder and CEO of UltraOral Ltd., a bio-science technology company based in Israel and
focused on oral health, systemic health and cognitive health solutions. Dr Sanders has over a decade and a
half of experience leading multi-disciplinary oral technology projects and bringing them to market.

#OralHealthInnovation #MucosalDelivery #DrugDeliverySystems #OralMedicineResearch #BiomedicalInnovation #OralHealthTechnology #NextGenDrugDelivery #TransmucosalTherapy #OralHealthCare #SmartDrugDelivery #SystemicHealthSupport #OralDrugDelivery #InnovativeTherapeutics #OralBiotechnology #MucosalTissueResearch #PrecisionMedicineOral #HealthcareInnovation #ClinicalDrugDelivery #AdvancedOralCare #TherapeuticPlatforms #OralSystemicLink #OralDiseasePrevention #RegenerativeOralMedicine #NovelDrugPlatforms #IntraoralTherapy #OralBiomaterials #OralHealthSolutions #DrugDeliveryInnovation #FutureOfOralCare #OralSystemicHealth #NextLevelOralCare #BiopharmaceuticalDelivery #SmartTherapeutics #OralMedicineAdvances #InnovativeOralResearch #OralTissueEngineering #DrugDeliveryTechnology #OralHealthcareFuture #OralTherapeuticsPlatform #NovelOralSystems #TranslationalOralResearch #ClinicalOralMedicine #MucosalTherapeutics #InnovativeDrugDesign #OralDiseaseManagement #BiotechOralCare #OralHealthResearch #TherapeuticInnovation #SystemicHealthApplications #OralDrugDiscovery

Upcoming Conference:
4th International Dental Advanced Dentistry, and Oral Health UCG Congress | September 9–11, 2025 | Novotel Al Barsha, Dubai, UAE